Buzz in the chat
The conversations physicians are having inside the longevitydocs™ network, one thread per story. Member discussion, not clinical guidance.
Learning TRT: guidelines, commercial courses or an AI-built curriculum?
A request for a good TRT course turned into a debate about where physicians should actually learn testosterone therapy.
After the FDA crackdown: what cash-pay clinics are doing about compounded GLP-1s
Members compared branded direct programs, oral options and the shrinking price gap with compounders.
Should everyone with elevated Lp(a) take aspirin?
Cardiologists in the network agreed on a targeted answer: aspirin when there is plaque or real genetic burden, not for a high number alone.
Are NAD+ infusions safe?
A physician with 20 years in longevity practice argued that the post-infusion lift is not what patients think it is.
CAC 149, almost all in the LAD: what would you do next?
A 49-year-old with good lipids and a concentrated calcium score prompted a clear consensus on the next test.
Midjourney's body scanner: hype or hardware?
An ultrasound body scanner launched in a spa setting split the chat between physics, regulation and false positives.
Verve-102: one-shot PCSK9 gene editing is not ready for patients
Remarkable science, the chat agreed, with too many unknowns to recommend.
Testosterone pens: the option most physicians are not using
Members pointed to a prefilled autoinjector that works in men and women.
GHK-Cu: topical beats injectable
A dermatologist in the network made the case for topical use after microneedling.
Stem cells: promise versus noise
A neurosurgeon's viral reel questioning stem cell therapy split the room.
Teenagers are using peptides
A physician reported high schoolers on retatrutide, GHK-Cu and tesamorelin, with a parent reconstituting the vials.
Perimenopausal weight gain is a diagnostic window, not a discipline failure
Dr. Catherine Johnson laid out how she works up and treats women who gain weight in perimenopause despite unchanged habits.
HRT after breast cancer: the case for individualized risk
Dr. Jordan Emont argued that many survivors are denied hormone therapy on the strength of trials that used regimens few physicians prescribe today.
Tirzepatide or semaglutide for alcohol cravings?
Physicians who prescribe both compared what they see in clinic, and flagged a practical risk when patients on GLP-1s drink.
Beta-blockers before a Cleerly CTA in bradycardic athletes
Should you hold metoprolol in a patient who sleeps in the low 40s? Cardiologists in the network gave clear thresholds.
Ferritin of 482 with normal iron studies: what next?
A 24-hour thread across gastroenterology, cardiology and longevity medicine on a deceptively simple lab result.
HRV: are doctors built different?
A question about magnesium and WHOOP turned into a debate about whether physicians carry a low-HRV phenotype.
Rapamycin and rising LDL: are we reading the wrong lipid?
A thread on climbing LDL and triglycerides under mTOR inhibition ended with a sharper question: whether standard lipid panels are the right instrument at all.
GLP-1s and hair loss: nutrition, or something more?
A rechallenge case drew a nutritional consensus, then a dermatologist argued some patients show more than weight-loss shedding.
Are GLP-1s stealing joy?
Physicians compared notes on anhedonia on GLP-1 agonists, and whether genetics and hormones predict who gets it.
AI scribes, HIPAA and decision support: what the chat is using
Members compared the AI tools they use for documentation, automation and clinical questions.
Cord blood banking: what physicians recommend to families
A practical question about where to store umbilical cord stem cells drew clear recommendations.
Physicians are sharing lab contracts to negotiate with Quest and Labcorp
When Quest pushed back on one member's rate request, colleagues shared their own numbers.
How do you measure senescent cell load in clinic?
Physicians asked how to decide who needs senolytics and how to tell whether they worked. Nobody has a clean answer yet.
Is HRV becoming a moral compass instead of a clinical metric?
Members asked whether we track HRV because it improves outcomes or because it feels meaningful.
Does spermidine promote cancer growth?
A new paper linking spermidine to tumor proliferation set off a familiar pattern in the chat.
Lp(a) in practice: what longevity physicians are actually doing
From an unexpected drop on a GLP-1 to stubborn non-responders, the chat compared notes on one of the hardest lipid problems in longevity medicine.
Medspa madness: physicians are cleaning up after the wellness boom
From Miami to Connecticut, members described patients arriving after unsupervised injections, and a medspa now selling stem cells.
HRT, coronary calcium and the stroke that split the room
A menopausal patient with a CAC of 92 on transdermal estradiol started a debate on clot risk, plaque and PFO that physicians across specialties weighed in on.
